Related Experiment Video
Updated: Apr 28, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Advanced heart failure in patients infected with human immunodeficiency virus: is there equal access to care?
Nir Uriel1, Nadav Nahumi2, Paolo C Colombo2
1Division of Cardiology, University of Chicago, Chicago, Illinois.
Insights
Most heart centers avoid treating advanced heart failure in HIV patients, citing risks and contraindications. This highlights unequal access to care and the need for provider education on modern HIV therapies.
Area of Science:
- Cardiology
- Infectious Diseases
- Transplantation Medicine
Background:
- Human immunodeficiency virus (HIV) infection is now a chronic condition for over 1 million Americans.
- Cardiovascular disease, including advanced heart failure (HF), is a leading cause of morbidity and mortality in the HIV-positive population.
- Advances in antiretroviral therapy have improved outcomes for HIV patients, necessitating re-evaluation of treatment guidelines for comorbidities.
Purpose of the Study:
- To assess current attitudes and practices regarding advanced heart failure therapies in human immunodeficiency virus (HIV)-infected patients.
- To investigate the utilization and perceived contraindications for heart transplantation (HT) and left ventricular assist device (LVAD) implantation in HIV-positive individuals.
- To identify barriers to care for advanced heart failure in the HIV-positive population.
Main Methods:
- A survey was distributed to 103 American and 9 Canadian heart transplantation (HT) centers.
- The survey collected data on attitudes and outcomes related to heart transplantation (HT) and left ventricular assist device (LVAD) implantation in HIV-infected patients.
- Responses were gathered via fax, email, or telephone.
Main Results:
- Only 18 heart transplants (HTs) were performed in HIV-positive patients, with high short-term survival but limited long-term data (63% at 5 years).
- A significant majority of centers (92%) have never performed HT in HIV-positive patients, with 57% citing HIV status as a contraindication due to organ scarcity, immunosuppression concerns, or drug interactions.
- Similarly, 76% of centers have never implanted a left ventricular assist device (LVAD) in HIV-positive patients, with 20% listing HIV as a contraindication, primarily due to concerns about device-related infections.
Conclusions:
- The majority of heart centers either contraindicate or have no experience treating advanced heart failure in HIV-positive patients.
- These findings indicate disparities in access to advanced cardiovascular care for individuals living with HIV.
- There is a critical need for enhanced education among cardiovascular healthcare providers regarding the efficacy and safety of modern HIV therapies and their implications for advanced HF treatment.
Background:
Human immunodeficiency virus (HIV) infection has evolved from a highly stigmatized disease with certain progression to acquired immunodeficiency syndrome (AIDS) to a chronic disease affecting over 1 million Americans. With the success of current anti-retroviral therapies, cardiovascular disease, including advanced heart failure (HF), will be a major cause of morbidity and mortality in this population.
Methods:
A survey concerning heart transplantation (HT) and left ventricular assist device (LVAD) implantation attitudes and outcomes in HIV-infected patients was distributed to 103 American and 9 Canadian HT centers via fax, e-mail or telephone.
Results:
Eighty-nine centers (79%) responded. Eighteen HTs were performed in HIV(+) patients with 1-, 2- and 5-year survival of 100%, 100% and 63%, respectively. Eighty-two centers (92%) have never performed HT in HIV(+) patients and 51 centers (57%) marked HIV(+) status as a contraindication. Rationales for contraindication included: (1) high-risk patients should be avoided given the scarcity of organ supply (59%); (2) immunosuppression required for HT may induce progression to AIDS (51%); and (3) drug interactions may worsen patients' clinical outcomes (49%). Thirty-five left ventricular assist device (LVAD) implantations in HIV(+) patients were reported. Sixty-eight centers (76%) have never implanted an LVAD in an HIV(+) patient and 21 centers (20%) marked HIV(+) status as a contraindication, of which 61% indicated concern for device-related infection.
Conclusions:
Most centers either explicitly consider HIV(+) status as a contraindication for or have never treated HIV(+) patients with advanced HF therapy. Our findings suggest unequal access to care and underscore the need to educate cardiovascular health-care providers on progress made with HIV therapies.
Related Concept Videos
Sexually Transmitted Infections
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Heart Failure I: Introduction
Retrovirus Life Cycles

